Introduction
Patients with heart failure (HF) are often burdened with multiple co-morbidities, 1,2 and HF patients with e.g. diabetes, 3 chronic obstructive pulmonary disease (COPD), 4, 5 or anaemia 5, 6 bear a worse prognosis than similar HF patients without these conditions. Despite the consensus that extra-cardiac diseases affect the prognosis and treatment of HF patients, 2, 7 very little information is known about the cumulative burden of multiple extra-cardiac co-morbidities. 5, 8, 9 Although most HF intervention trials have focused on therapies aimed at the cardiovascular (CV) system, it is believed that extra-cardiac diseases also influence CV outcomes in HF patients. 2, 5, 9 While several therapies have proven efficacious for patients with HF with reduced ejection fraction (HFrEF), 10 -13 no therapy has been found to reduce morbidity and mortality in patients with HF with preserved ejection fraction (HFpEF).
14 -17 It has been proposed that a greater demographic and co-morbid burden in HFpEF patients may explain why medications with predominantly cardiac effects will not affect mortality and morbidity outcomes to a significant degree. 18 Thus, estimating the contribution of disease burden to CV outcomes in both types of HF patients may help predict the maximal achievable risk reduction of treatments aimed at decreasing the cardiac or extra-cardiac disease burden. We utilized a HF risk score for mortality -the MAG-GIC risk score -as an externally validated framework to discern the relative contribution of demographic, cardiac and extra-cardiac disease burden to clinically important CV morbidity and mortality outcome 19 in the broad spectrum of HF patients with both HFrEF and HFpEF enrolled in the CHARM programme. Population attributable risks (PARs) for each of demographic, cardiac and extra-cardiac disease burden were visualized continuously across the left ventricular ejection fraction (LVEF) spectrum.
Methods
We utilized data from the previously reported CHARM trials. 10 In summary, 7599 chronic HF patients, New York Heart Association (NYHA) classes II-IV, were randomized to receive either placebo or candesartan (target dose 32 mg) in addition to optimal medical HF therapy. Patients were enrolled in the CHARM-Alternative 20 or CHARM-Added 21 trials if their LVEF was ≤40%, and in the CHARM-Preserved 15 trial if their LVEF was >40%. Patients were followed for a median of 38 months. All CV events during follow-up were adjudicated by an independent endpoints committee, who classified events according to pre-specified criteria. 22 This study complies with the Declaration of Helsinki, and the research protocol was approved by all relevant ethics committees and informed consent was obtained from the subjects (or their legally authorized representative).
Calculation of burden
To discern and quantify each risk component -demographic, cardiac and extra-cardiac -from the total risk profile of each patient, we utilized the externally validated MAGGIC risk score, 19 13 variables identified as being highly significant, and an integer risk score created using model estimates of the predictive strength of each variable. A higher score was associated with increased risk of mortality (www.heartfailurerisk.org).
Definition of demographic, cardiac and extra-cardiac disease burden
In this analysis, we utilized all 13 baseline risk factors identified in the MAGGIC score, which were collected in the CHARM trial from patients recruited from North America only (n = 2743). Data for calculation of the MAGGIC score were possible in 2675 patients (98%).
We grouped the 13 variables into three sub-categories each representing demographic (age, gender), cardiac risk factors or disease [LVEF, NYHA class, systolic blood pressure, HF hospitalization within 18 months, no beta-blocker use, no angiotensin-converting enzyme (ACE) inhibition], and extra-cardiac risk factors or disease (body mass index, diabetes, COPD, creatinine, current smoker). Using the MAG-GIC integer score, the sum of each sub-component reflected the total burden of either demographic, cardiac or extra-cardiac disease and was calculated individually for all patients. A total maximum score of 57 points was obtainable across all categories (cardiac disease burden, 0-26; extra-cardiac burden, 0-19; demographic burden, 0-16).
Statistical analysis
All baseline characteristics pertaining to the risk categories were summarized as counts (%), mean ± standard deviation, median [interquartile range (IQR)], or as geometric mean ± 95% confidence intervals, due to right-skewed distribution (creatinine). Restricted cubic spline models were used to depict the mean levels of demographic, cardiac disease and extra-cardiac disease burden across the LVEF spectrum. Using time-to-event data for outcomes of all-cause death, CV death, HF hospitalization, fatal and non-fatal myocardial infarction (MI), fatal and non-fatal stroke, Cox proportional hazard modelling was used to estimate the PAR for each component with respect to each of the examined outcomes. The PAR is summarized as per cent (±95% confidence intervals), and estimates the hypothetical reduction of incidence rates if all patients had no burden in a specific sub-component (e.g. cardiac disease burden = 0). Attributable risks may add up to greater than 100%. Combined attributable risks are calculated by multiplication. For example, attributable risks of 70% and 60% would produce a combined attributable risk of 1 − (1 − 0.70) × (1 − 0.60) = 88%. Because risks are multiplicative, they are displayed graphically on a log scale so that relative importance can be seen visually. Non-significant negative PAR estimates were considered as 0. The Cox proportional hazards models were adjusted for all categories (demographic, cardiac and extra-cardiac) and analyses were stratified according to HF group (HFrEF vs. HFpEF) as well as continuously across the LVEF spectrum. In order to estimate the PAR for each component as a function of continuous LVEF, we used Cox proportional hazards models including interaction terms between that component and LVEF (modelled using both linear and quadratic terms), while adjusting for the other two categories. For any value of LVEF, we then estimated the average additional risk experienced by the actual study patients relative to a hypothetical population with the same LVEF value but who possessed zero points for that score component. PAR estimates of cardiac and extra-cardiac categories stratified to HFrEF and HFpEF were compared using the delta method under the assumption of independence, resulting in potentially conservative All values are counts (%), except creatinine which is summarized as geometric mean ± 95% confidence intervals, burden as median [interquartile range], and age, LVEF, systolic BP and BMI as mean ± standard deviation. ACE, angiotensin-converting enzyme; BMI, body mass index; BP, blood pressure; COPD, chronic obstructive pulmonary disease; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association. * Bronchodilator use at randomization.
P-values.
Risk of CV outcomes and progressive extra-cardiac burden was analysed using Cox proportional hazard spline models adjusted for each category of cardiac disease and demographic burden.
Results

Baseline characteristics and risk distribution
In total, 2675 patients from North America with baseline data available for calculation of the MAGGIC score were included in this study. The median follow-up time was 37 months. The 2675 included patients from North America differed from the original CHARM cohort at baseline by having higher incidences of hypertension, prior coronary procedures, diabetes, COPD/asthma, and active smoking, but fewer prior HF hospitalizations and males. By construction, each unit increase of the MAGGIC score should correspond to an increased event rate of 1.11. Similarly, the observed relationship with overall mortality in CHARM was: hazard ratio (HR) 1.12 (1.10-1.13), P < 0.001 for every integer point increase of the MAGGIC score (C statistic: 0.70). The HR for other outcomes examined were: CV death HR factors that were used to calculate the MAGGIC score are listed in Table 1 . The median (IQR) MAGGIC score in this sub-population of CHARM was 22 (10, 33), range 2-43. The total score of all three categories was higher in the HFrEF group compared with the HFpEF group. The greater score in HFrEF patients was mostly due to a progressively higher burden of cardiac risk factors in patients with lower LVEF (P < 0.001), with extra-cardiac burden only slightly increasing as LVEF decreased (P < 0.001). Conversely, demographic burden was greater among patients with higher LVEF (P < 0.001; Table 1 and supplementary material online, Figure S1 ).
The ratio of cardiac:extra-cardiac risk factors was much higher in patients with lower LVEF (Figure 1) . As LVEF increased, so did the contribution of demographic risk factors, making it the biggest contributor of all categories in patients with higher LVEF.
Association between progressive extra-cardiac disease burden and cardiovascular outcomes
The risk of HF hospitalization and CV death increased in a linear fashion with higher extra-cardiac co-morbid burden, irrespective of LVEF ( Figure 2 ; both P < 0.001). Similar analyses were carried out for outcomes of MI and stroke, which all showed a significantly positive relationship with increasing extra-cardiac burden, irrespective of LVEF (data not shown).
Relative contribution of demographic, cardiac and extra-cardiac disease burden to cardiovascular outcomes across the left ventricular ejection fraction spectrum
In patients with lower LVEF, the contribution of cardiac disease burden to all-cause death, CV death, and HF was greater than extra-cardiac disease burden. In contrast, in patients with higher LVEF, extra-cardiac disease burden contributed more to all outcomes examined -death, CV death, HF, MI, stroke -compared with cardiac disease burden, cardiac disease burden having a non-significant contribution to outcomes of MI and stroke Table S1 and Table S4 , as are estimates of PAR with renal function grouped as a cardiac risk factor as sensitivity analysis (supplementary material online, Table S2 ), and PAR without renal function, but with all patients from the CHARM programme (n = 7599) (supplementary material online, Table S3 ).
Discussion
We found that in a broad spectrum of HF patients from North America the distribution of cardiac, extra-cardiac, and demographic risk factors differed by ejection fraction. patients with higher LVEF. There was a clear association between the incremental burden of extra-cardiac disease and risk of CV outcomes, irrespective of LVEF. Cardiac disease burden contributed most to outcomes of death and HF hospitalization in patients with lower LVEF, whereas extra-cardiac burden contributed more than cardiac burden to death, HF hospitalization, MI, and stroke in patients with higher LVEF.
In contrast with studies that reported crude prevalence rates of co-morbidity, 9, 18 in this analysis we were able to account for the cumulative contribution of multiple diseases, as well as how these change with ejection fraction. Because cardiac risk factors were more prevalent in patients with lower LVEF, the ratio of cardiac to extra-cardiac risk factors was much higher in these patients, a finding which is consistent with the higher rates of adverse CV events HFrEF patients experienced, compared with HFpEF patients, in registries 9 and in the CHARM 15,20,21 and DIG 23, 24 trials which included both HF populations. The finding that extra-cardiac risk factors were at least as prevalent in lower LVEF patients compared with higher LVEF patients was also reported in a non-selective ambulatory cohort of US veterans with HF. 9 In a large Medicare registry with chronic HF patients, a cumulative number of non-cardiac co-morbidities were associated with increased risk of hospitalization for HF. 8 We also noted a linear relationship between the burden of extra-cardiac disease and HF hospitalization, as well as for the outcomes of CV death, MI and stroke. Our study adds clarity by exploring several adjudicated CV outcomes, and using selected risk factors that were validated from the MAGGIC risk score. Our finding of strong associations . . . . . . . . . . . . . . between extra-cardiac burden and CV outcomes suggests that extra-cardiac disease burden does indeed influence different CV outcomes, and that there is no upper threshold where incremental burden does not translate into a higher incidence of these outcomes.
The CHARM data allowed us to model the relative contributions of demographic, cardiac, and extra-cardiac disease burden across the entire LVEF spectrum, making these estimates applicable to all chronic HF patients, irrespective of how HF patients are sub-grouped (e.g. HFmrEF, 7 HFpEF with systolic impairment 25 ) . A key finding from this study is the clarification of the relative contributions of modifiable (cardiac and extra-cardiac disease) and non-modifiable (demographics) categories to outcomes across the LVEF range. Our finding in HFrEF patients that cardiac disease burden was the greatest contributor to death, CV death, and HF hospitalization, would suggest that modifying the cardiac disease burden might translate into benefits in these outcomes. In contrast, HFpEF patients had a non-significant contribution from cardiac disease burden to death and CV death in our study. In HFrEF outcome trials such as MERIT-HF, 13 CONSENSUS, 26 and PARADIGM-HF 27 that tested cardiac disease-modifying treatments (beta-blockers, ACE inhibition, angiotensin-neprilysin inhibition), death, CV death, and HF progression was reduced compared with placebo. In contrast, HFpEF patients treated with ACE inhibitors, angiotensin receptor blockers, or mineralocorticoid-receptor antagonists in the PEP-CHF (Perindopril for Elderly People with Chronic Heart Failure), 28 I-PRESERVE (Irbesartan in Heart Failure with Preserved Systolic Function), 16 CHARM-Preserved (Effects of Candesartan in Patients with Chronic Heart Failure and Preserved Left Ventricular Ejection Fraction), 15 and TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) 14 trials, did not have decreased risk of death or CV death. Our findings may help explain why cardiac disease-modifying treatments have not proven successful in alleviating the CV burden in HFpEF patients. The contribution of cardiac disease burden to CV outcomes may be relatively small, limiting the potential benefit of therapies that predominantly affect CV disease burden in patients with higher LVEF. Although we cannot infer that changing co-morbid burden changes outcomes, these data may aid in the planning of future trials by quantifying what modifiable categories are contributing most to CV outcomes and death at a given LVEF range. To our knowledge, this is the first analysis that quantifies how the relative contribution of co-morbidity and demographic factors influences risk in a CV population, and to show how this varies across the ejection fraction spectrum. As a method, this approach may prove useful beyond HF.
Some limitations of this analysis should be noted. Data from the CHARM study constituted ∼19% of the total data used for development of the MAGGIC score, although the score was designed to assess the risk of death. In addition, because CHARM was a clinical trial with specific inclusion and exclusion criteria, caution needs to be exercised when extrapolating these findings to other HF populations. Specifically, the co-morbid status of the CHARM population may differ from that found in other HF populations. These considerations should also be noted with the MAGGIC risk factors that were identified using patients from 31 cohort studies, 6 of which were randomized clinical trials. Although we confined our analysis to patients from North America in order to include creatinine, which was only measured in this subset, a sensitivity analysis including all patients in the CHARM programme (n = 7599) from the entire programme ( The relative contribution of cardiac, extra-cardiac, and demographic risk factors to CV outcomes is highly dependent on the arbitrary grouping of risk factors into categories. While estimates were affected by a different grouping, the overall differences between patients across the LVEF spectrum did not change.
In conclusion, the relative distribution and burden of cardiac, extra-cardiac disease, and demographics differs in HF patients depending on their LVEF. These data may help explain why cardiac disease-modifying medication proven to be efficacious in patients with HFrEF have not demonstrated the same benefits in patients with HFpEF.
Supplementary Information
Additional Supporting Information may be found in the online version of this article: Figure S1 . The distribution of the MAGGIC score risk factors across the left ventricular ejection fraction (LVEF) spectrum, grouped according to cardiac, extra-cardiac, or demographic component. Table S1 . The proportion of risk attributable to demographic, cardiac and extra-cardiac disease burden in all patients, and in HFrEF and HFpEF patients. Table S2 . The proportion of risk attributable to demographic, cardiac and extra-cardiac disease burden, where renal function is categorized as a cardiac co-morbidity. Table S3 . The proportion of risk attributable to demographic, cardiac and extra-cardiac disease burden, using all included CHARM subjects (n = 7599). Table S4 . The proportion of risk attributable to demographic, cardiac and extra-cardiac disease burden in HFrEF (LVEF <40%), HFmrEF (LVEF 40-49%), and HFpEF (LVEF ≥50%) patients.
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